Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.86 |
| ▸ | MEN1 | O00255 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | HBB | P68871 | 2/20 | 0.80 |
| ▸ | DDX5 | P17844 | 1/20 | 0.80 |
| ▸ | CASP1 | P29466 | 1/20 | 0.80 |
| ▸ | CASP7 | P55210 | 1/20 | 0.80 |
| ▸ | GLA | P06280 | 3/20 | 0.77 |
| ▸ | TP53 | P04637 | 2/20 | 0.77 |
| ▸ | HPGD | P15428 | 2/20 | 0.77 |
| ▸ | STAT6 | P42226 | 1/20 | 0.77 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | GMNN | O75496 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27764694 | 1.00 | TOP1 (0.86) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23929259 | 0.93 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16649109 | 0.93 | TOP1 (0.78) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23963902 | 0.93 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16649363 | 0.91 | TOP1 (0.79) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3138027 | 0.90 | TOP1 (0.82) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18251453 | 0.90 | TOP1 (0.73) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydroxycamptothecin SCHEMBL25875 | 0.89 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydroxycamptothecin SCHEMBL29350707 | 0.89 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydroxycamptothecin SCHEMBL29929278 | 0.89 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240084272-A1 | CYTOCHROME P450 MONOOXYGENASES AND USES THEREOF | UNIV BRITISH COLUMBIA (CA) | 2024-03-14 | — | — | US | claimed |
| WO-2022120490-A1 | CYTOCHROME P450 MONOOXYGENASES AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-06-16 | — | — | WO | claimed |
| US-6011042-A | POLYMERIC PRODRUGS ARE PREFERABLY ESTERS OF HYDROXYL-CONTAINING AROMATIC COMPOUNDS AND ARE FORMED BY REACTING A DESIRED AROMATIC, HYDROXYL-CONTAINING COMPOUND WITH A SUBSTANTIALLY NON-ANTIGENIC POLYMER | ENZON, INC. (US) | 2000-01-04 | — | — | US | claimed |
| US-20240084272-A1 | CYTOCHROME P450 MONOOXYGENASES AND USES THEREOF | UNIV BRITISH COLUMBIA (CA) | 2024-03-14 | — | — | US | disclosed |
| WO-2022120490-A1 | CYTOCHROME P450 MONOOXYGENASES AND USES THEREOF | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-06-16 | — | — | WO | disclosed |
| US-8367065-B2 | Targeted polymeric prodrugs containing multifunctional linkers | ENZON PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100233190-A1 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| EP-2073820-A2 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS | Enzon Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008034124-A2 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-0963988-B1 | Intermediates for making camptothecin and camptothecin analogs | UNIV NORTH CAROLINA STATE (US) | 2005-04-27 | — | — | EP | disclosed |
| EP-0923566-B1 | HIGH MOLECULAR WEIGHT POLYMER-BASED PRODRUGS | ENZON INC (US) | 2003-10-29 | — | — | EP | disclosed |
| US-5264579-A | D ring intermediates for the synthesis of camptothecin and camptothecin analogs | NORTH CAROLINA STATE UNIVERSITY (US) | 1993-11-23 | — | — | US | disclosed |
| US-5258516-A | Optically pure D,E ring intermediates useful for the synthesis of camptothecin and camptothecin analogs | NC STATE UNIVERSITY (US) | 1993-11-02 | — | — | US | disclosed |
| US-5254690-A | Alkoxymethylpyridine d-ring intermediates useful for the synthesis of camptpthecin and camptothecin analogs | NORTH CAROLINA STATE UNIVERSITY (US) | 1993-10-19 | — | — | US | disclosed |
| US-5247089-A | Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs | NORTH CAROLINA STATE UNIVERSITY (US) | 1993-09-21 | — | — | US | disclosed |
| US-5243050-A | Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs | NORTH CAROLINA STATE UNIVERSITY (US) | 1993-09-07 | — | — | US | disclosed |
| US-5212317-A | Methods and intermediates for the assymmetric synthesis of camptothecin and camptothecin analogs | NORTH CAROLINA STATE UNIVERSITY (US) | 1993-05-18 | — | — | US | disclosed |
| US-5200524-A | Camptothecin intermediates and method of making same | NORTH CAROLINA STATE UNIVERSITY (US) | 1993-04-06 | — | — | US | disclosed |
| US-5191082-A | Camptothecin intermediate and method of making camptothecin intermediates | NORTH CAROLINA STATE UNIVERSITY (US) | 1993-03-02 | — | — | US | disclosed |
| US-5162532-A | INTERMEDIATES AND METHOD OF MAKING CAMPTOTHECIN AND CAMPTOTHECIN ANALOGS | NORTH CAROLINA STATE UNIVERSITY (US) | 1992-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233190-A1 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS | PAICS, FCGRT, DNPEP | TOP1 1503/4885MEN1 2219/4885KMT2A 2107/4885 |
| US-20240084272-A1 | CYTOCHROME P450 MONOOXYGENASES AND USES THEREOF | CYP3A43, CYP11B2, CYP11B1 | TOP1 367/4885MEN1 2868/4885KMT2A 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.